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LEARNINGS FROM THE EVIDENCE PROJECT

Expanding Access and Method Choice:

Evidence of Client Self-administration of Injectables and Private Sector
Provision of Family Planning Services in Three West African Countries
Over the past two decades, the proportion of all women
of reproductive age (15–49 years old) using any form of
contraception more than doubled in sub-Saharan Africa
[1]. The demand for family planning (FP) satisfied by a
modern method increased from 24 percent in 1990 to 52
percent in 2015, yet about 17 percent of women still have
an unmet need for FP [2]. In West Africa, modern contraceptive method use remains low with approximately 18
percent of all women of reproductive age using a modern
method [3]. While in many West African countries FP services are offered for free through the public sector, there
are a number of reasons people may opt to use the private
sector for contraceptive supplies.
Governments across West Africa have expressed their
commitment to increasing access to voluntary FP through
global and regional initiatives such as FP2020 and the

KEY LESSONS
DMPA-SC, including self-injection, and drug shop
provision of injectable contraceptives were acceptable and reached new contraceptive users
as well as young people.
Women received high quality of care through
new/expanded service delivery channels in
Ghana and Nigeria.
Job aids and client tools provided ongoing, evidence-based support to providers and clients in
applying new skills.
Close collaboration with in-country partners and
stakeholders was crucial to develop contextualized approaches and foster research utilization.

Ouagadougou Partnership, and through targeted national
strategies. Ghana, Nigeria and Senegal, among other countries, have been exploring new strategies to expand access
to voluntary FP service delivery. Context-specific evidence
was needed for two promising strategies—1) task sharing
of FP services to private sector drug shops and pharmacies
and 2) introducing self-injection of subcutaneous depot
medroxyprogesterone acetate (DMPA-SC).

OUR IMPLEMENTATION SCIENCE
APPROACH
The Evidence Project used implementation science
(IS)—the strategic generation, translation, and use
of evidence—to strengthen, scale-up, and sustain
voluntary family planning (FP) services.
Our IS approach was driven by collaboration with
partners to: (1) define research priorities; (2) implement research activities; and (3) use evidence for
decision-making.

The Evidence Project collaborated with stakeholders in
Ghana, Nigeria, and Senegal to use implementation science (IS) to expand the evidence base on these promising approaches. In this brief, we describe key study results
from the three countries and how results have been used
to increase access to voluntary family planning and expand
method choice.

The Evidence Project explored
task sharing with drug shops
and pharmacies as well as selfadministration of injectables
to improve equitable access to
voluntary family planning
Previous studies have shown that task sharing contraceptive services to private sector drug outlets and including
self-administered methods in the method mix can improve
access to voluntary FP services, especially for underserved
and marginalized populations [4–9]. Task sharing is defined
as “an expansion of the levels of health providers who
can appropriately deliver health services” [5]. By sharing
certain tasks across provider types, some benefits of task
sharing include increasing access to and availability of contraception and giving higher skilled clinicians more time to
use their specialized skills or focus on complex tasks [5].
Self-administration of DMPA-SC has the potential to improve access, choice, continuation, and autonomy in countries that allow women to self-administer DMPA-SC in or
outside of a health facility [6,7].
From 2013 to 2019, the Evidence Project collaborated with
ministries of health (MOHs) in Ghana, Nigeria, and Senegal to explore ways to improve access to voluntary contraceptive services through task sharing and self-administered
methods. Figure 1 provides an overview of the studies
conducted in Ghana [10], Nigeria [11,12], Senegal [13–15].
Full descriptions of the study design, results, and IS process can be found on the Evidence Project website.
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This brief is part of a series of briefs synthesizing
evidence and lessons learned through the project.
Other briefs include:
• Expanding access to voluntary FP through new
approaches to workplace interventions
• Innovating and validating measures of complex
concepts
These briefs and all other Evidence Project publications can be found at: http://evidenceproject.popcouncil.org/.

DMPA-SC, including self-injection,
and drug shop provision of
injectable contraceptives were
acceptable and reached new
contraceptive users as well as young
people
In Ghana, 568 women who sought FP services from a public health facility and voluntarily chose DMPA-SCi (after
receiving FP counseling) were interviewed following their
initial visit and up to two additional times, coinciding with

DMPA-SC AND TASK SHARING REACHED
NEW USERS
• 41% of DMPA-SC clients in Ghana were first-time
FP users
• 42% of injectable clients in Nigeria began a new
episode of use at their visit to a PPMV

Sayana® Press (a registered trademark of Pfizer Inc.) was the brand of
DMPA-SC used in this study.
i

FIGURE 1 . S TUDY IMPLEMENTATION SITES*

SENEGAL FP SNAPSHOT

GHANA FP SNAPSHOT

NIGERIA FP SNAPSHOT

18% modern contraceptive prevalence
rate (mCPR)

18% mCPR

11% mCPR

41% FP demand satisfied by modern
methods

36% FP demand satisfied by modern
methods

Injectables (6%), implants (4%), and
pills (4%)—most commonly used modern
methods

Implants (3%), male condoms (3%), and
injectables (2%)—most commonly used
modern methods

STUDY OVERVIEW

STUDY OVERVIEW

• Assessed the feasibility and acceptability of DMPA-SC self- and/or
provider-administered
injection
through public sector channels

• Assessed the feasibility and acceptability of providing injectables by
trained proprietary medicine vendors
(PPMVs)

• Conducted interviews with 1) providers pre- and post-training and
2) clients over 6-month period after
initiating DMPA-SC use

• Conducted multiple interviews with
1) PPMVs over 9-month period and
2) clients of PPMVs over 9-month period

55% FP demand satisfied by modern
methods
Injectables (6%); implants (6%); and
pills (3%)—most commonly used modern
methods

STUDY OVERVIEW
Phase 1: Exploratory study
• Explored barriers to and opportunities
for the provision of voluntary FP by private pharmacies
• Conducted literature and legal reviews, secondary data analysis, and
key informant interviews
Phase 2: Pilot study
• Trained private pharmacy staff and
assessed the feasibility of these staff
to offer counseling, and oral and injectable contraceptives
• Conducted interviews with private
pharmacies and used mystery clients
to assess FP counseling skills of staff
from participating pharmacies

*Country FP snapshots include data for all women 15–49 years old from the
latest Demographic and Health Surveys for Ghana (2014), Nigeria (2018),
and Senegal (2018) [16].

their contraceptive follow-up injections. At each injection,
women were given the option to self-inject DMPA-SC or
have the provider administer it [10]. Of the 378 women
who continued to use DMPA-SC through their third injection, 72 percent chose to self-inject (either at home or
on-site) while 28 percent chose provider administration. As
the Ghana Health Service scales up DMPA-SC nationally,
it will be important for the scale-up program to provide
women with options for administration modes.
In Nigeria, 561 clients were interviewed within five days
of receiving injectable contraceptives from private sector
Patent and Proprietary Medicine Vendors (PPMVs). Forty-two percent of clients reported starting a new episode
of injectable contraceptive use and 61 percent of all clients
interviewed had not previously received injectable contraceptives from a PPMV. Common reasons for choosing
PPMVs included convenient location, anonymous care,
personally knowing the PPMV, and no waiting time [11].
Clients also reported high satisfaction with the services
received by PPMVs and nearly all (99 percent) said they

would go back to the PPMV for their next injection. These
results confirm that PPMVs represent an important and
feasible outlet for increasing access to voluntary FP in Nigeria.

YOUNG PEOPLE FOUND NEW APPROACHES
AND SOURCES OF FP ACCEPTABLE
• In Ghana, 33% of DMPA-SC clients were under 24
(n=185), and 98% of them intended to continue
using DMPA-SC after their first injection. Among
young women who chose self-injection at their initial visit and were still using DMPA-SC six months
later (n=54), 94% continued to self-inject.
• In Nigeria, 12% of PPMV clients were under 24
years of age (n=69), and after their first injection,
all said they would return to the same PPMV to
continue their method.
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Before the pilot study in Senegal was initiated, the Evidence
Project explored opportunities for and barriers to private
pharmacy provision of FP services. Through a literature
review, the Evidence Project found that 43–46 percent
of existing private pharmacy clients would be interested
in directly obtaining oral or injectable contraceptives from
private pharmacies [14]. Secondary data analysis of data
collected by L’Agence pour le Développement du Marketing Social (ADEMAS) also found that private pharmacies
distribute a larger percentage of short-acting contraceptive
methods compared to public health facilities [15]. The legal review found that Article 569 from the April 1954 law
states that “the operation of a pharmacy is incompatible
with the practice of another profession, particularly that
of a medical practitioner, a veterinarian, a midwife, or a
dentist.” This means that while private pharmacies can sell
condoms and emergency contraceptives over the counter
and oral, injectable implant, and IUD contraceptivesii with
a prescription, they are not permitted to prescribe or administer contraceptive methods [14].
Methods such as the injectable, implant, and IUD may be purchased
with a prescription but are administered by a qualified heath professional.
ii

Women received high quality
services
Quality of care in FP includes the interpersonal relations
and exchange of information between a provider and a client. It can be measured in terms of quality of care offered
by providers through observations of counseling and mystery clients, and quality of care received as reported by clients (typically through client exit interviews). In Ghana and
Nigeria, client exit interviews were used to capture quality
of care received by clients from public sector providers and
PPMVs. In Senegal, mystery clients were used to observe
the quality of care offered by private pharmacies. Figure 2
shows the proportion of FP clients in Ghana and Nigeria
who reported that they received information on seven quality of care questions during their initial visit.iii In Ghana,
62 percent of clients reported receiving information on all
seven components of quality of care. For individual quesUnder the Evidence Project, Jain et al. [17] validated 22- and 10-item
measures to assess quality of care received by clients during FP visits
with providers or frontline health workers. The measures cover four domains of quality of care: respectful care, information exchange about
method selection, effective use of the selected method, and continuity
of contraceptive use and care. The study in Nigeria took place before
these measures were validated and thus the measures are not included in this brief but are available here.
iii

F IG U R E 2 . C LI E N T S’ RE PO RT S O F QUA L IT Y O F CA RE REC EIVED IN GH A NA A ND NIGERIA

99

Told when to return for follow-up/
when next injection is due

98

92
94
91

Asked reason for visit

95
84

Asked about previous FP/
injectable experience

93
82

Told about potential
side effects of the method

91
79

Told how to manage side effects
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Ghana (n=568)

97

Told about other methods

0%

Nigeria (n=561)

95

Client felt comfortable asking
questions

82
25%
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50%

75%

100%

tions, receipt of information ranged from 99 percent of
women who reported that they were told when their next
injection was due to 79 percent of women who reported
that they were told how to manage side effects. These data
suggest that clients received high quality of care from the
public sector providers participating in the Ghana study.
In Nigeria, 66 percent of women reported receiving all
seven components of quality of care. Almost all women
(98%) reported that they were told when to return for their
next injection. While 91 percent reported that they were
told about the potential side effects of their injectable contraceptive method, fewer (82%) reported being told how to
manage those side effects. These results suggest that clients
enrolled in this study received high quality of care from
PPMVs trained in the study in Nigeria.
In Senegal, 94 percent of mystery clients observed that
the pharmacy staff asked them about their past experience
with FP, 82 percent were asked if they had a preferred
method in mind, and 92 percent discussed other FP methods with pharmacy staff (data not shown). However, some
aspects of quality of care were observed less frequently
such as discussing side effects (33%), warning signs (28%),
and how to manage the side effects of the method (24%)
(data not shown).

Job aids and client tools provided
ongoing, evidence-based support to
providers and clients to help them
apply new skills
In all three countries, trained providers were equipped with
relevant job aids and received subsequent supportive supervision and monitoring visits. The results from all three
country studies suggest that job aids can support providers
effectively who are new to offering a service and enable clients to effectively self-administer their contraceptive method if they choose.
In Ghana, the Evidence Project used job aids and client
tools for home and self-injection that were developed by
PATH. Providers were given a checklist to record the steps
clients took when practicing DMPA-SC self-injection on
dummy models. The majority of providers reported that
they had memorized the steps of the checklist and therefore did not systematically refer to it when observing clients
practicing self-injection of DMPA-SC. For clients who selected home self-injection, women were given self-injection
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instruction sheets and calendars to remind them of their
next DMPA-SC injection. Nearly all clients (95%) reported
using the calendar and most who used it (90%) found it
very useful.
In Nigeria, job aids supported PPMVs in remembering important, detailed information. The majority of
PPMVs (86%) reported using the World Health Organization’s Medical Eligibility Criteria Wheel, Population Council’s Balanced Counseling Strategy Plus cards, and/or FHI
360 DMPA screening checklist. PPMVs’ reported use of
job aids was associated with higher levels of injectable contraceptive knowledge nine months after the training [18].
In the Senegal pilot study, mystery clients observed that in
nearly three-fourths (73%) of their visits, the private pharmacy staff used a job aid while providing FP counseling.

Close collaboration with in-country
partners and stakeholders was
crucial to develop contextualized
approaches and foster research
utilization
In all three countries, the Evidence Project worked closely with key partners and stakeholders, including ministries
of health, professional associations, donors and development partners, regulatory agencies, nongovernmental organizations, and private-sector institutions. These close
and collaborative relationships informed study design and
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public and private sectors with support from several partners. The GHS used several approaches employed during
the study for scaling up DMPA-SC, including home self-injection. The GHS replicated and extended the cascade
training approach used in the study to accelerate national
scale-up. The same master trainers that were trained for the
self-injection pilot study went on to then train regional resource persons in all 16 administrative regions in the country using the same job aids, checklists, and client tools that
were adapted for this study. In addition, the study contributed evidence to inform national procurement plans and
routine monitoring of DMPA-SC services in Ghana. Daily
logbooks, monthly registers, and health information systems were recently revised to enable monitoring of DMPA-SC counseling, administration (specifying provider- or
self-administered), and commodity tracking.

implementation as well as adaptation of global materialsiv
and intervention approaches to each country’s context.
In addition, ongoing stakeholder engagement fostered research utilization and offered opportunities for sustainability and scale up.
In Ghana, study implementation was overseen by the Ghana Health Service (GHS) and guided by a national technical advisory group (TAG). This TAG, led by GHS, was
instrumental in informing the study design; adapting intervention approaches and training materials; and conducting
monitoring visits to study sites. For instance, based on the
TAG’s input, concerns about waste management and safe
disposal practices were incorporated into the study design
and data collection.
Study findings were used subsequently by the GHS to inform national scale-up plans for DMPA-SC and self-injection. Research results, for instance, demonstrated the feasibility of providing clients with a puncture-proof container
to store used DMPA-SC devices and instructing them to
return the container to the facility for final disposal. This
evidence-informed safe disposal practice was incorporated
into the national scale-up plans for home self-injection.
In April 2019, Ghana began expanding access to
DMPA-SC through service delivery channels in both the
Materials consulted included the World Health Organization’s Medical
Eligibility Criteria [19], PATH’s DMPA-SC training curriculum [20, 21],
FHI 360’s screening checklists for oral and injectable contraceptives
[22, 23], and the Population Council’s Balanced Counseling Strategy
Plus [24].
iv

6

E X PA N D I N G AC C E S S A N D M E T H O D C H O I C E

EXPANDED ACCESS TO AND OPTIONS FOR
DMPA-SC ADMINISTRATION IN GHANA
Evidence generated on the feasibility and acceptability of self-injection in Ghana has informed the
government’s national DMPA-SC scale-up plans, including approaches to waste management and safe
disposal practices.

In Nigeria, the Evidence Project worked in partnership
with the Federal Ministry of Health (FMOH), state ministries of health from across the country’s geopolitical
zones, the National Association of Patent and Proprietary
Medicines, and several other nongovernmental partners
in a multi-phased IS approach. This group of partners informed the study design and development of FP training
materials adapted for PPMVs, and participated in study
monitoring visits. At the design phase, for instance, the
FMOH co-hosted a stakeholder meeting to garner support for expanding the study design from only assessing
PPMVs’ ability to counsel and refer clients for injectable
contraceptives to also assess PPMVs’ ability to administer
injectables. Furthermore, a collaborative group of government and nongovernment partners reviewed initial results
and learning from two states, Oyo and Nasarawa, to refine
the training curriculum and implementation and data collection plans for four additional states: Bauchi, Cross River,
Ebonyi, and Cross River.
Evidence from across multiple Nigerian states on the feasibility and acceptability of PPMV provision of injectables

GREATER METHOD CHOICE AVAILABLE
THROUGH PPMVS IN NIGERIA
Evidence on the feasibility and acceptability of
PPMVs providing injectables, in addition to other
short-acting contraceptive methods, has informed
the country’s DMPA-SC scale-up plans. The government, in collaboration with the Population Council
and other partners, is currently piloting a tiered
accreditation system for PPMVs and community
pharmacists to provide more methods, including
implants.

was used to expand method choice for women in Nigeria. The FMOH and other partners used study results to
include PPMVs in the national DMPA-SC scale up plans.
Also, building on the Evidence Project’s work, two additional states are now piloting PPMV provision of injectables under another project, supported by the Clinton
Health Access Initative. In addition, the government continues to explore formalizing the role of PPMVs in providing a range of voluntary FP methods, including injectables
and potentially implants, through a tiered accreditation
system under the IntegratE Project. Partners in Nigeria,
including the Population Council and others, are currently
collaborating to pilot this new tiered accreditation system
to continue to expand method choice through PPMVs and
community pharmacists.
In Senegal, the Evidence Project collaborated with champions within the MOH, national research organizations, and
professional associations to conduct an exploratory study
which led to the MOH requesting a follow-up pilot study.
During the pilot, the Evidence Project continued to work
with representatives and trainers from the Directorate of
Maternal and Child Health alongside representatives from
the Pharmacists Order of Senegal to adapt the Nigeria
PPMV training curriculum, in addition to other global and
local learning materials [19–25], for use with private pharmacies. The training, for instance, was shortened based
on guidance from the Pharmacists Order to ensure participation from busy private pharmacists. Additional modifications were also required since the legal framework in
Senegal restricted services participating pharmacies could
offer, even with full support from the MOH in collaboration with key stakeholders in the public and private sectors.
While pharmacists and assistant pharmacists were trained
on injectable administration and could practice on dummy
models, they could not provide injectables to interested cli-

ents since pharmacists were not formally linked to a health
center that could address potential complications.
Despite the reduced training length for private pharmacy
staff in Senegal, absenteeism was common and private
pharmacists’ consistent participation in the training was
hampered by their competing business demands. Legal restrictions may also have deterred their full participation in
the training. Additional evidence is needed about how to
tailor training formats and continued advocacy is needed to
foster a more favorable legal environment for private pharmacies to provide a wider range of contraceptive methods. Despite these challenges, results of the study are being used by the Directorate of Maternal and Child Health
and other key partners to advocate for the private sector
to play a larger role in health service delivery through legal
and policy changes.

Ways forward
The findings from all three countries demonstrate the potential for increased access to voluntary FP through task
sharing and self-administration of injectables. Additionally, the studies demonstrate the benefit of using context-responsive IS to assess feasibility and acceptability of new
service delivery options. Provision of a broad range of
FP methods through drug shops, pharmacies, and self-administration offer important opportunities for women,
including new users and young people. It is also essential
to ensure that women receive high-quality care from both
newly trained providers and existing providers offering
new services. Ongoing commitment from national governments and collaboration among a variety of stakeholders
will continue to support evidence-informed decisions to
expand access and method choice.
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